NASDAQ : NUVL
Nuvalent, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 123.96 USD (At close: Jul 14, 2026) · Market cap 9.83B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.83B |
| Enterprise Value | 8.55B |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 73.90M |
| Shares Outstanding | 79.33M |
| Shares Change (YoY) | +9.05% |
| Shares Change (QoQ) | +4.73% |
| Owned by Insiders (%) | 1.99% |
| Owned by Institutions (%) | 65.92% |
| Float | 49.75M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 141.63 |
| PB Ratio | 8.33 |
| P/TBV Ratio | 8.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.14 |
| Quick Ratio | 15.88 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -41.19% |
| Return on Assets (ROA) | -22.51% |
| Return on Invested Capital (ROIC) | -25.10% |
| Return on Capital Employed (ROCE) | -35.11% |
| Weighted Average Cost of Capital (WACC) | 10.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.92M |
| Employee Count | 234 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 596,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.14 |
| 52-Week Price Change | +53.17% |
| 50-Day Moving Average | 111.73 |
| 200-Day Moving Average | 103.20 |
| Relative Strength Index (RSI) | 67.59 |
| Average Volume (20 Days) | 2,166,629 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.91M |
| Short Previous Month | 3.12M |
| Short % of Shares Out | 3.67% |
| Short % of Float | 5.85% |
| Short Ratio (days to cover) | 0.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -438.90M |
| Pretax Income | -449.48M |
| Net Income | -450.07M |
| EBITDA | n/a |
| EBIT | -438.90M |
| Earnings Per Share (EPS) | -$6.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.29B |
| Total Debt | n/a |
| Net Cash | 1.29B |
| Net Cash Per Share | $16.23 |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 14.89 |
| Working Capital | 1.23B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -312.79M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.05% |
| Shareholder Yield | -9.05% |
| Earnings Yield | -4.58% |
| FCF Yield | n/a |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $125.13 |
| Price Target Difference | 0.94% |
| Analyst Consensus | Hold |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |